FindTrial
Sign In

tolododekin alfa

DRUG3 trials

Sponsors

Ankyra Therapeutics, Inc

Conditions

Advanced Solid TumorCutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)Cutaneous TumorMalignant Solid TumorMetastasis to Soft TissueMetastatic Solid TumorNon Small Cell Lung Cancer

Phase 1

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RecruitingNCT06171750
Ankyra Therapeutics, IncAdvanced Solid Tumor, Cutaneous Squamous Cell Carcinoma, Cutaneous Tumor +6
Start: 2024-01-19End: 2027-06-01Target: 97Updated: 2026-03-06
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
RecruitingNCT07027514
Ankyra Therapeutics, IncNon Small Cell Lung Cancer
Start: 2025-10-22End: 2028-12-31Target: 60Updated: 2025-11-18
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Not yet recruitingNCT07100925
Ankyra Therapeutics, IncCutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant, Solid Tumor +1
Start: 2025-12-15End: 2030-12-31Target: 20Updated: 2025-08-03

Related Papers

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial
Nature Communications2025-09-29
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.
Journal of Clinical Oncology2025-05-28
Abstract CT039: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)
Cancer Research2025-04-253 citations
A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
Journal of Clinical Oncology2024-06-01